First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Published:2020-06 Issue:6 Volume:21 Page:821-831
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Janjigian Yelena Y,Maron Steven B,Chatila Walid K,Millang Brittanie,Chavan Shweta S,Alterman Carly,Chou Joanne F,Segal Michal F,Simmons Marc Z,Momtaz Parisa,Shcherba Marina,Ku Geoffrey Y,Zervoudakis Alice,Won Elizabeth S,Kelsen David P,Ilson David H,Nagy Rebecca J,Lanman Richard B,Ptashkin Ryan N,Donoghue Mark T A,Capanu Marinela,Taylor Barry S,Solit David B,Schultz Nikolaus,Hechtman Jaclyn F

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Incidence of gastroesophageal junction cancer continues to rise: analysis of Surveillance, Epidemiology, and End Results (SEER) database;Bartel;Proc Am Soc Clin Oncol,2019

3. Comprehensive molecular characterization of gastric adenocarcinoma;Nature,2014

4. Integrated genomic characterization of oesophageal carcinoma;Nature,2017

5. Genetic predictors of response to systemic therapy in esophagogastric cancer;Janjigian;Cancer Discov,2018

Cited by 268 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions;International Journal of Cancer;2024-09-14

2. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma;Nature Communications;2024-08-09

3. Prediction of HER2 Expression in Gastric Adenocarcinoma Based On Preoperative Noninvasive Multimodal 18F-FDG PET/CT Imaging;Academic Radiology;2024-08

4. HER-2 positive gastric cancer: Current targeted treatments;International Journal of Biological Macromolecules;2024-08

5. Advances in the treatment of human epidermal growth factor receptor 2-positive gastric cancer;International Journal of Clinical Oncology;2024-07-31